Pericarditis clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for

  • CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation

    Sorry, not currently recruiting here

    Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocker for recurrent pericarditis remain free of pericarditis recurrence while receiving CardiolRx.

    at UC Irvine

  • REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

    Sorry, in progress, not accepting new patients

    The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.

    at UCSD

Last updated: